KYMR — Kymera Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $7.16bn
- $6.49bn
- $47.07m
- 36
- 10
- 67
- 30
Annual income statement for Kymera Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 34 | 72.8 | 46.8 | 78.6 | 47.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 80.3 | 173 | 208 | 244 | 309 |
| Operating Profit | -46.3 | -101 | -161 | -166 | -262 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -45.6 | -100 | -155 | -147 | -224 |
| Net Income After Taxes | -45.6 | -100 | -155 | -147 | -224 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -45.6 | -100 | -155 | -147 | -224 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -54.6 | -100 | -155 | -147 | -224 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.23 | -2.09 | -2.87 | -2.52 | -2.92 |
| Dividends per Share |